Trends in the global immuno-oncology landscape

Jun Tang, Laura Pearce, Jill O’Donnell-Tormey & Vanessa M. Hubbard-Lucey
Nature Reviews Drug Discovery volume 17, pages 783–784 (2018)

The approval of ipilimumab in 2011 to treat melanoma marked the beginning of the cancer immunotherapy revolution, which has progressively changed the paradigm of cancer care in recent years. Since then, 11 new cancer immunotherapies have been approved, and these new therapies have quickly become the standard of care for many cancer types.

To inform the cancer immunotherapy community of the advances in the rapidly evolving field, the Cancer Research Institute, a nonprofit group dedicated to research in cancer immunotherapy for more than 65 years, conducted a comprehensive survey of the global immuno-oncology (IO) landscape in September 2017 (Ann. Oncol. 29, 84–89; 2017). One year later, in September 2018, we have conducted another landscape survey. In this report, we compare the two surveys and provide longitudinal analyses of the evolution of the global IO landscape.

Article Site:

Original Document:

Related Post

Biocon’s Target Factory
views 26
South Korea's 8-year effort to create an integrated platform for novel target and lead development provides an academic drug discovery model for...
전세계 신약후보물질 수집하는 中 바이오제약사...
views 268
(바이오스펙테이터=장종원기자) 기사입력 : 2018-07-12 15:48|수정 : 2018-07-12 15:48 중국 바이오제약기업들이 전세계 신약 후보물질을 공격적으로 인수하고 있다. 막대한 자금을 앞세워 상대적으로 부족한 신약 파이프라인을 강화하기 위한...
의약바이오컨버젼스연구단 석사연구원 채용...
views 1580
                                                                  <서울대학교 의약바이오컨버젼스연구단 석사연구원 채용>    미래창조과학부 글로벌프런티어 연구개발사업의 일환으로, 혁신을 통...
전염병 치료 타겟으로의 ARS, Biochemical Pharmacology Mini Re...
views 754
  Biocon 세부 과제 책임자이신 한국생명공학연구원 김명희 박사님(사진 왼쪽)과 김성훈 단장님이 작업한 Mini Review 논문이 Biochemical Pharmacology에 발표 되었습니다. 논문 제목은 "Aminoacyl-tRNA ...


We're not around right now. But you can send us an email and we'll get back to you, asap.


©2010-2019 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?

Skip to toolbar